Xuh4A74zzv | 2421260-43-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: Xuh4A74zzv
• 英文别名: (3S)-3-[6-[4-[[1-[4-[(E)-1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
• CAS: 2421260-43-5
• 化学式: C₄₅H₄₉N₅O₄
• 分子量: 723.9
• InChiKey: BMBNNENJXSGVDJ-APTBUVIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  54
• 可旋转键数：
  9
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  96.4
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF
  申请人：ACCUTAR BIOTECHNOLOGY INC.

  公开号：US20200157078A1

  公开（公告）日：2020-05-21

  The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

  本公开涉及具有雌激素受体α降解活性的新化合物，包含这些化合物的药物组合物，以及它们在预防和治疗癌症及相关疾病和症状中的应用。
• Compounds having estrogen receptor alpha degradation activity and uses thereof
  申请人：ACCUTAR BIOTECHNOLOGY INC.

  公开号：US10696659B2

  公开（公告）日：2020-06-30

  The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

  本公开涉及具有雌激素受体α降解活性的新型化合物、含有此类化合物的药物组合物，以及它们在预防和治疗癌症及相关疾病和病症中的用途。
• COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF
  申请人：Accutar Biotechnology Inc.

  公开号：US20200299264A1

  公开（公告）日：2020-09-24

  The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
• COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER
  申请人：Accutar Biotechnology

  公开号：US20210213012A1

  公开（公告）日：2021-07-15

  Provided herein are pharmaceutical combinations, compositions, and methods of using a compound with estrogen receptor (ER) degradation activity, such as a compound of formula (I) or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate thereof, wherein R 1 , Y, R 22 , R 33 , R 2 , p, X 3 , X 4 , and Z are defined herein and a cyclin-dependent kinase (CDK) inhibitor.